Gene Expression Profiling to Predict Outcome After Chemoradiation in Head and Neck Cancer

Purpose

The goal of the present study was to improve prediction of outcome after chemoradiation in advanced head and neck cancer using gene expression analysis.

Materials and Methods

We collected 92 biopsies from untreated head and neck cancer patients subsequently given cisplatin-based chemoradiation (RADPLAT) for advanced squamous cell carcinomas (HNSCC). After RNA extraction and labeling, we performed dye swap experiments using 35k oligo-microarrays. Supervised analyses were performed to create classifiers to predict locoregional control and disease recurrence. Published gene sets with prognostic value in other studies were also tested.

Results

Using supervised classification on the whole series, gene sets separating good and poor outcome could be found for all end points. However, when splitting tumors into training and validation groups, no robust classifiers could be found. Using Gene Set Enrichment analysis, several gene sets were found to be enriched in locoregional recurrences, although with high false-discovery rates. Previously published signatures for radiosensitivity, hypoxia, proliferation, “wound,” stem cells, and chromosomal instability were not significantly correlated with outcome. However, a recently published signature for HNSCC defining a “high-risk” group was shown to be predictive for locoregional control in our dataset.

Conclusion

Gene sets can be found with predictive potential for locoregional control after combined radiation and chemotherapy in HNSCC. How treatment-specific these gene sets are needs further study.

Introduction

Head and neck cancer is the fifth most common cancer, with an incidence of 780,000 new cases a year worldwide (1). For most patients, there are several treatment options such as radiotherapy, chemoradiation, radiation with cetuximab, surgery, or a combination of these modalities. Prediction of tumor behavior, such as metastatic potential and response to different treatments, would enable a more individualized approach by selecting the optimal treatment. To date, the most important factors predicting outcome are tumor volume 2, 3, 4 and stage (TNM classification). However, neither biologic behavior nor response to therapy can be fully explained by these factors. Thus there remains an urgent need to find better ways to predict outcome and aid treatment choice for individual patients.

Over the last few years, gene expression profiling using microarrays has provided a powerful new approach to study biologic processes and has led to the discovery of predictive markers for several tumor types. 5, 6, 7. Choi (8) reviewed many of the head and neck cancer studies, most of which focused on genetic differences between HNSCC and normal epithelia. Chung et al (9) defined four subtypes of head and neck squamous cell carcinomas (HNSCC) based on gene expression patterns associated with different clinical outcomes and were also able to predict metastatic cervical lymph node status. They subsequently identified high- and low-risk groups for recurrence of mainly surgically treated patients with and without postoperative radiotherapy or chemotherapy with a 75-gene classifier (10). O'Donnell et al. (11), Warner et al. (12), and Roepman et al. (13) also found signatures that could predict regional metastases formation in HNSCC. Recently, Braakhuis et al. (14) tried to predict distant metastases in HNSCC using gene expression profiling, but without success.

Most studies have focused on biologic processes associated with prognosis and have not specifically addressed treatment response. Several studies have found signatures associated with prognosis in a wide variety of situations; for example, the “wound” signature (15), the hypoxia signature (16), a stem cell signature (17), and a chromosome instability signature (18). These signatures, however, appear to be general monitors of malignancy or aggressive behavior, because they have been found to apply to several different cancer types and in patients given a variety of different treatments. They are thus neither disease specific nor treatment specific.

In head and neck cancer, combined concurrent chemotherapy and radiotherapy (chemoradiation) is the preferred treatment modality for advanced stages, and although response to initial treatment is good, almost 30% of patients develop a locoregional recurrence (19). The aim of the present study was to find an expression profile that could predict outcome after chemoradiation, which would allow better choice of treatments for individual patients and improve insights into causes of failure.